DK2488523T3 - N-((1r, 2s, 5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazol[1,5-a]1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamid, en dobbeltmodulator af chemokinreceptor-aktivitet, krystallinske former ogfremgangsmåder - Google Patents

N-((1r, 2s, 5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazol[1,5-a]1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamid, en dobbeltmodulator af chemokinreceptor-aktivitet, krystallinske former ogfremgangsmåder

Info

Publication number: DK2488523T3
Authority: DK; Denmark
Prior art keywords: tert; chemokinreceptor; crystallinic; butylpyrazol; oxopyrrolidin
Prior art date: 2009-10-13

Application number

DK10768153.8T

Other languages

English (en)

Inventor

Percy H Carter

Robert J Cherney

Victor W Rosso

Jun Li

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-13

Filing date

2010-10-12

Publication date

2014-02-10

2010-10-12 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2014-02-10 Application granted granted Critical

2014-02-10 Publication of DK2488523T3 publication Critical patent/DK2488523T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Oncology (AREA)
Psychiatry (AREA)

DK10768153.8T 2009-10-13 2010-10-12 N-((1r, 2s, 5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazol[1,5-a]1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamid, en dobbeltmodulator af chemokinreceptor-aktivitet, krystallinske former ogfremgangsmåder DK2488523T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25097809P	2009-10-13	2009-10-13
PCT/US2010/052288 WO2011046916A1 (en)	2009-10-13	2010-10-12	N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes

Publications (1)

Publication Number	Publication Date
DK2488523T3 true DK2488523T3 (da)	2014-02-10

Family

ID=43063940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10768153.8T DK2488523T3 (da)	2009-10-13	2010-10-12	N-((1r, 2s, 5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazol[1,5-a]1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamid, en dobbeltmodulator af chemokinreceptor-aktivitet, krystallinske former ogfremgangsmåder

Country Status (28)

Country	Link
US (3)	US8383812B2 (da)
EP (2)	EP2664620A3 (da)
JP (1)	JP5759999B2 (da)
KR (1)	KR20120102052A (da)
CN (1)	CN102648201B (da)
AR (1)	AR078627A1 (da)
AU (1)	AU2010306968B2 (da)
BR (1)	BR112012008650B1 (da)
CA (1)	CA2777563A1 (da)
CL (1)	CL2014000753A1 (da)
CO (1)	CO6460737A2 (da)
DK (1)	DK2488523T3 (da)
EA (2)	EA201490744A1 (da)
ES (1)	ES2442897T3 (da)
HR (1)	HRP20140072T1 (da)
IL (2)	IL219121A0 (da)
MX (1)	MX2012003720A (da)
NZ (2)	NZ613580A (da)
PE (1)	PE20121349A1 (da)
PL (1)	PL2488523T3 (da)
PT (1)	PT2488523E (da)
RS (1)	RS53131B (da)
SI (1)	SI2488523T1 (da)
SM (1)	SMT201400020B (da)
TN (1)	TN2012000132A1 (da)
TW (1)	TW201120042A (da)
WO (1)	WO2011046916A1 (da)
ZA (1)	ZA201305994B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8383812B2 (en) *	2009-10-13	2013-02-26	Bristol-Myers Squibb Company	N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CN106456641A (zh) *	2014-07-17	2017-02-22	参天制药株式会社	眼后段疾病的预防或治疗剂
JOP20190040A1 (ar)	2016-09-14	2019-03-10	Novartis Ag	توليفة من ناهضات fxr
RU2019110779A (ru)	2016-09-14	2020-10-15	Новартис Аг	Новые схемы введения агонистов fxr
HUE058049T2 (hu) *	2017-07-20	2022-06-28	Bristol Myers Squibb Co	Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására
KR20200112904A (ko) *	2018-01-22	2020-10-05	브리스톨-마이어스 스큅 컴퍼니	암을 치료하는 조성물 및 방법
AU2020383625A1 (en) *	2019-11-13	2022-05-05	Rapt Therapeutics, Inc.	Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof
JP2023538533A (ja)	2020-08-07	2023-09-08	ブリストル－マイヤーズスクイブカンパニー	線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
WO2023092049A1 (en) *	2021-11-19	2023-05-25	Bristol-Myers Squibb Company	Azirine pharmaceutical compositions
WO2024240025A1 (zh) *	2023-05-22	2024-11-28	无锡瓴方生物医药科技有限公司	一种联合用药物组合物及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE812551C (de)	1949-05-13	1951-09-03	Basf Ag	Verfahren zur Herstellung von Pyrrolidon-Derivaten
JPS6383082A (ja)	1986-09-26	1988-04-13	Takeda Chem Ind Ltd	テトラヒドロフランカルボン酸誘導体の製造法
CA2084800A1 (en)	1991-12-16	1993-06-17	Joseph P. Vacca	Hiv protease inhibitors with an internal lactam ring
GB9515411D0 (en)	1995-07-27	1995-09-27	Pharmacia Spa	N-(4-substituted-benzyl)-2-aminolactam derivatives
US5827875A (en)	1996-05-10	1998-10-27	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
UA51716C2 (uk)	1996-07-08	2002-12-16	Авентіс Фармасьютікалз Продактс Інк.	Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6054579A (en)	1997-06-26	2000-04-25	Leukosite, Inc.	Synthesis of substituted lactams
GB9716656D0 (en)	1997-08-07	1997-10-15	Zeneca Ltd	Chemical compounds
CN1291892A (zh)	1998-01-27	2001-04-18	阿温蒂斯药物制品公司	取代的氧代氮杂杂环基因子Xa抑制剂
HUP0101329A3 (en)	1998-01-29	2002-07-29	Aventis Pharmaceuticals Inc Co	Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compounds and a cyclyzed compounds there from
US6492553B1 (en)	1998-01-29	2002-12-10	Aventis Pharamaceuticals Inc.	Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB9803228D0 (en)	1998-02-17	1998-04-08	Zeneca Ltd	Chemical compounds
US6541208B1 (en)	1998-03-17	2003-04-01	University Of Maryland Biotechnology Institute	Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
AU7354900A (en)	1999-09-09	2001-04-10	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
AU2001253108A1 (en)	2000-04-03	2001-10-15	Bristol-Myers Squibb Pharma Company	Cyclic lactams as inhibitors of a-beta protein production
EP1268433A1 (en)	2000-04-03	2003-01-02	Bristol-Myers Squibb Pharma Company	Cyclic lactams as inhibitors of a-beta-protein production
US6620823B2 (en)	2000-07-11	2003-09-16	Bristol-Myers Squibb Pharme Company	Lactam metalloprotease inhibitors
EP1345941A1 (fr)	2000-12-20	2003-09-24	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
AR035720A1 (es) *	2000-12-20	2004-07-07	Bristol Myers Squibb Pharma Co	Derivados de amida ,composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de quimioquinas
WO2002060859A2 (en)	2000-12-20	2002-08-08	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
WO2002078679A2 (en)	2001-03-29	2002-10-10	Topo Target Aps	Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
GB0114867D0 (en)	2001-06-18	2001-08-08	Merck Sharp & Dohme	Therapeutic agents
DE10135043A1 (de)	2001-07-11	2003-01-30	Bayer Cropscience Gmbh	Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren
WO2003075853A2 (en)	2002-03-08	2003-09-18	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
TW200307667A (en) *	2002-05-06	2003-12-16	Bristol Myers Squibb Co	Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
WO2004022536A1 (en)	2002-09-04	2004-03-18	Glenmark Pharmaceuticals Limited	New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
TW200508224A (en)	2003-02-12	2005-03-01	Bristol Myers Squibb Co	Cyclic derivatives as modulators of chemokine receptor activity
US7338975B2 (en) *	2003-02-12	2008-03-04	Bristol-Myers Squibb Co.	Lactams as modulators of chemokine receptor activity
US7230133B2 (en) *	2003-05-01	2007-06-12	Bristol-Myers Squibb Company	Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7291615B2 (en) *	2003-05-01	2007-11-06	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
WO2004110376A2 (en)	2003-06-06	2004-12-23	Merck & Co., Inc.	Ccr-2 antagonists for treatment of neuropathic pain
US7378409B2 (en) *	2003-08-21	2008-05-27	Bristol-Myers Squibb Company	Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
TWI354664B (en) *	2003-08-21	2011-12-21	Bristol Myers Squibb Co	Cyclic derivatives as modulators of chemokine rece
US20050043392A1 (en) *	2003-08-21	2005-02-24	Carter Percy H.	Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US7163937B2 (en)	2003-08-21	2007-01-16	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
US7317019B2 (en) *	2003-08-21	2008-01-08	Bristol Myers Squibb Co.	N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
KR20080044360A (ko)	2004-07-30	2008-05-20	화이자 프로덕츠 인코포레이티드	Ｃｃｒ2 매개 질병 또는 장애의 치료방법
EP1802602A1 (en) *	2004-09-28	2007-07-04	Janssen Pharmaceutica N.V.	Substituted dipiperdine ccr2 antagonists
US7687508B2 (en)	2006-07-28	2010-03-30	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) *	2006-07-28	2009-12-08	Bristol-Myers Squibb Company	N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en)	2006-07-28	2010-03-02	Bristol-Myers Squibb Company	Modulators of chemokine receptor activity, crystalline forms and process
US8383812B2 (en) *	2009-10-13	2013-02-26	Bristol-Myers Squibb Company	N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes

2010
- 2010-10-11 US US12/901,614 patent/US8383812B2/en active Active
- 2010-10-12 BR BR112012008650-2A patent/BR112012008650B1/pt active IP Right Grant
- 2010-10-12 EA EA201490744A patent/EA201490744A1/ru unknown
- 2010-10-12 AU AU2010306968A patent/AU2010306968B2/en not_active Ceased
- 2010-10-12 PE PE2012000461A patent/PE20121349A1/es active IP Right Grant
- 2010-10-12 DK DK10768153.8T patent/DK2488523T3/da active
- 2010-10-12 ES ES10768153.8T patent/ES2442897T3/es active Active
- 2010-10-12 CA CA2777563A patent/CA2777563A1/en not_active Abandoned
- 2010-10-12 PT PT107681538T patent/PT2488523E/pt unknown
- 2010-10-12 EA EA201270602A patent/EA020486B1/ru not_active IP Right Cessation
- 2010-10-12 KR KR1020127012167A patent/KR20120102052A/ko not_active Withdrawn
- 2010-10-12 RS RS20140026A patent/RS53131B/en unknown
- 2010-10-12 CN CN201080056536.5A patent/CN102648201B/zh active Active
- 2010-10-12 SI SI201030457T patent/SI2488523T1/sl unknown
- 2010-10-12 NZ NZ613580A patent/NZ613580A/en not_active IP Right Cessation
- 2010-10-12 EP EP13180657.2A patent/EP2664620A3/en not_active Withdrawn
- 2010-10-12 NZ NZ599311A patent/NZ599311A/xx unknown
- 2010-10-12 JP JP2012534282A patent/JP5759999B2/ja not_active Expired - Fee Related
- 2010-10-12 MX MX2012003720A patent/MX2012003720A/es active IP Right Grant
- 2010-10-12 HR HRP20140072AT patent/HRP20140072T1/hr unknown
- 2010-10-12 WO PCT/US2010/052288 patent/WO2011046916A1/en active Application Filing
- 2010-10-12 PL PL10768153T patent/PL2488523T3/pl unknown
- 2010-10-12 EP EP10768153.8A patent/EP2488523B8/en active Active
- 2010-10-13 TW TW099134977A patent/TW201120042A/zh unknown
- 2010-10-13 AR ARP100103741A patent/AR078627A1/es unknown
2012
- 2012-03-23 TN TNP2012000132A patent/TN2012000132A1/en unknown
- 2012-04-05 IL IL219121A patent/IL219121A0/en active IP Right Grant
- 2012-04-12 CO CO12060326A patent/CO6460737A2/es active IP Right Grant
2013
- 2013-01-22 US US13/746,389 patent/US8618101B2/en active Active
- 2013-08-08 ZA ZA2013/05994A patent/ZA201305994B/en unknown
- 2013-11-27 US US14/091,388 patent/US8906920B2/en active Active
2014
- 2014-01-05 IL IL230319A patent/IL230319A/en active IP Right Grant
- 2014-02-17 SM SM201400020T patent/SMT201400020B/xx unknown
- 2014-03-26 CL CL2014000753A patent/CL2014000753A1/es unknown

Also Published As

Publication number	Publication date
EP2664620A2 (en)	2013-11-20
KR20120102052A (ko)	2012-09-17
EP2488523B1 (en)	2013-11-20
NZ599311A (en)	2013-08-30
WO2011046916A1 (en)	2011-04-21
SMT201400020B (it)	2014-05-07
EP2664620A3 (en)	2014-03-05
PL2488523T3 (pl)	2014-04-30
CA2777563A1 (en)	2011-04-21
IL230319A (en)	2014-07-31
US8618101B2 (en)	2013-12-31
TN2012000132A1 (en)	2013-09-19
TW201120042A (en)	2011-06-16
IL219121A0 (en)	2012-06-28
EA201490744A1 (ru)	2014-11-28
AU2010306968B2 (en)	2015-04-09
BR112012008650A2 (pt)	2016-04-19
JP2013507444A (ja)	2013-03-04
CL2014000753A1 (es)	2014-08-29
ES2442897T3 (es)	2014-02-14
ZA201305994B (en)	2014-05-28
EA201270602A1 (ru)	2012-10-30
EA020486B1 (ru)	2014-11-28
AU2010306968A1 (en)	2012-05-03
US20140088109A1 (en)	2014-03-27
AR078627A1 (es)	2011-11-23
NZ613580A (en)	2014-07-25
RS53131B (en)	2014-06-30
JP5759999B2 (ja)	2015-08-05
SI2488523T1 (sl)	2014-01-31
EP2488523A1 (en)	2012-08-22
CN102648201A (zh)	2012-08-22
PE20121349A1 (es)	2012-10-15
EP2488523B8 (en)	2014-04-16
US20110086857A1 (en)	2011-04-14
CO6460737A2 (es)	2012-06-15
HK1174614A1 (en)	2013-06-14
CN102648201B (zh)	2015-06-24
BR112012008650B1 (pt)	2021-07-13
PT2488523E (pt)	2014-02-21
US8906920B2 (en)	2014-12-09
MX2012003720A (es)	2012-04-30
US20130158039A1 (en)	2013-06-20
US8383812B2 (en)	2013-02-26
HRP20140072T1 (hr)	2014-02-28

Publication	Publication Date	Title
DK2488523T3 (da)	2014-02-10	N-((1r, 2s, 5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazol[1,5-a]1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamid, en dobbeltmodulator af chemokinreceptor-aktivitet, krystallinske former ogfremgangsmåder
CL2013002241A1 (es)	2013-12-13	Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc.
WO2008102563A1 (ja)	2008-08-28	血管攣縮の治療剤又は予防剤
CL2008000379A1 (es)	2008-10-24	Composicion farmaceutica que comprende en combinacion, un primer ingrediente activo que es n-[2-(dietilamino)etil]n-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoxi]propanamida o una sal y un segundo ingr
CL2017001853A1 (es)	2018-05-11	Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (divisional de solicitud n°1707-2016).
WO2011061330A3 (de)	2011-07-21	Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
BRPI0822885A2 (pt)	2015-06-30	Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
DK2381925T3 (da)	2017-06-26	Anvendelse af en opskummelig sammensætning, der i det væsentlige er fri for farmaceutisk aktive bestanddele, til behandling af human hud
UY34061A (es)	2012-11-30	Cocristales de ácido cítrico y l-prolina de (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorofenil)tiofen-2-il)metil)-4-metilfenil)-6-(hidroximetil)tetrahidro-2h-piran-3,4,5-triol
IL225167A (en)	2016-03-31	Annotations (para-methoxy) phenyl-sulfonamide, n- (isobutyl), n - [(r2) - hydroxy- (r3) - benzyl-profile]
WO2009040666A3 (en)	2009-12-30	Treatment of graft-versus-host disease
EA201200484A1 (ru)	2012-12-28	Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
GEP20146078B (en)	2014-04-10	Processes for pharmaceutically active agent manufacture
AR090874A1 (es)	2014-12-10	Formulacion
CL2007002194A1 (es)	2008-02-08	Compuesto n-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-2-oxo-3-(6-(trifluorometil)quinazolin-4-ilamino)pirrolidin-1-il)ciclohexil)-acetamida; forma cristalina del compuesto; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como dia
WO2009158646A8 (en)	2010-03-25	Therapeutic compounds and related methods of use
AR062112A1 (es)	2008-10-15	Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
GEP20146195B (en)	2014-11-10	Crystal of amide compound
HK1204475A1 (en)	2015-11-20	Crystalline forms of 1- (3 -tert-butyl- 1 - p-tolyl- 1h- pyrazol- 5 -yl) -3- (5-fluoro-2- (1- ( 2 - hydroxyethyl) - indazol- 5 -yloxy) benzyl) urea hydrochloride
UY31059A1 (es)	2008-10-31	Formulaciones de aminoacido n-halogenado
WO2009092040A3 (en)	2012-06-21	Topical pain formulation
EA201001125A1 (ru)	2011-04-29	Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
BRPI0907482A2 (pt)	2017-05-30	amidas do ácido 3-(4-fluorfenil)-3hidroxi-2-amino-propiônico e compostos relacionados com atividade analgésica
IL272034B (en)	2022-06-01	Process for preparing n-((1r, 2s, 5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,a-5][1, 3, 5) Triazine-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide
HU0401422D0 (en)	2004-09-28	Use of l-arginine as vasoaktive ingredient absorbing through skin for external application